Home
News
In Focus
Business
Metro
Nation
World
Sports
Feature
Opinion
View more 禄Opinion Columns
Wan LixinOpinion deputy editor of Shanghai Daily
City-born architect lists inspiration behind his designs in a new book
Digitization helps preserve, disseminate intangible cultural heritage
Sunday
- Subscribe
Related News
Cancer warning: All girls in Europe need HPV vaccines
Source: Agencies |
September 6, 2012, Thursday
|
Print Edition
Print Edition
ALL girls in Europe should be immunised against the human papillomavirus (HPV) that causes cervical cancer and current vaccine coverage rates are far too low, European Union health officials said yesterday.
In new advice about tackling the virus, the European Centre for Disease Prevention and Control said that while 19 out of 29 countries in the region had introduced HPV vaccine programs, vaccination rates were as low as 17 percent in some.
Cervical cancer is the second most common cancer in women worldwide, with about 500,000 new cases and 250,000 deaths each year, according to the World Health Organisation. Virtually all cases are linked to genital infection with HPV, the most common viral infection of the reproductive tract.
British drugmaker GlaxoSmithKline and US rival Merck & Co make the only two HPV vaccines licensed for use in Europe.
The ECDC said that in 2010, only Portugal and Britain had vaccination coverage rates above 80 percent for the target groups of girls aged between about 10 and 14 years.
It urged health authorities to step up their efforts to get more girls vaccinated, saying recent research studies had shown the shots to be safe and effective, as well as cost-effective.
"We public health authorities, frontline healthcare workers and parents alike have a shared responsibility to protect thousands of women from cervical cancer," said Marc Sprenger, the ECDC's director. "European countries may need to examine why HPV vaccination coverage rates are not higher and strengthen their vaccination campaigns accordingly."
While recent studies have also shown that HPV shots can also help protect boys from various types of cancer - including oral, anal and penile cancers - the ECDC said its recommendations did not as yet seek to include young men in vaccination programs.
"The personal benefit of the vaccine for men in terms of cancer prevention is very low," it said in a statement. "Including boys in the current HPV vaccination programmes is unlikely to be cost-effective."
In new advice about tackling the virus, the European Centre for Disease Prevention and Control said that while 19 out of 29 countries in the region had introduced HPV vaccine programs, vaccination rates were as low as 17 percent in some.
Cervical cancer is the second most common cancer in women worldwide, with about 500,000 new cases and 250,000 deaths each year, according to the World Health Organisation. Virtually all cases are linked to genital infection with HPV, the most common viral infection of the reproductive tract.
British drugmaker GlaxoSmithKline and US rival Merck & Co make the only two HPV vaccines licensed for use in Europe.
The ECDC said that in 2010, only Portugal and Britain had vaccination coverage rates above 80 percent for the target groups of girls aged between about 10 and 14 years.
It urged health authorities to step up their efforts to get more girls vaccinated, saying recent research studies had shown the shots to be safe and effective, as well as cost-effective.
"We public health authorities, frontline healthcare workers and parents alike have a shared responsibility to protect thousands of women from cervical cancer," said Marc Sprenger, the ECDC's director. "European countries may need to examine why HPV vaccination coverage rates are not higher and strengthen their vaccination campaigns accordingly."
While recent studies have also shown that HPV shots can also help protect boys from various types of cancer - including oral, anal and penile cancers - the ECDC said its recommendations did not as yet seek to include young men in vaccination programs.
"The personal benefit of the vaccine for men in terms of cancer prevention is very low," it said in a statement. "Including boys in the current HPV vaccination programmes is unlikely to be cost-effective."
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
